赛拉思实验性血液癌症免疫疗法临床试验成功降低死亡风险
STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
赛拉思的实验性血液癌症免疫疗法galinpepimut-S在三期临床试验中将急性髓系白血病晚期患者的死亡风险降低了41%,达到主要研究终点。
临床试验结果显示某药显著降低急性髓系白血病患者的死亡风险,具有重要治疗意义。
The unexpected result is good news for patients with acute myeloid leukemia
![]()
Nov. 17, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.
On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia (AML) — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said.
In a column published in September, I predicted galinpepimut would fail to prolong survival in the Phase 3 study.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
Senior Writer, Biotech
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
来源:STAT 主站 · statnews.com